CLEANER-Vac大腔血栓清除系统真实世界多中心200例分析
该回顾性多中心研究纳入200例症状性静脉血栓患者,评估CLEANER-Vac系统的操作有效性、安全性及临床价值;结果显示平均血栓清除率88.0%,76.0%患者达到≥90%清除,总体并发症率2.4%且均为轻微入路部位血肿,无器械相关严重不良事件。
要点
- CLEANER-Vac系统平均血栓清除率88.0%,76.0%患者达到≥90%清除。
- 总体并发症率2.4%,均为轻微入路部位血肿,无器械相关严重不良事件。
- 平均器械使用时间8.0分钟,平均每次手术2.4次器械通过。
核心结论
- 在200例患者队列中,CLEANER-Vac系统显示高操作有效性(平均血栓清除率88.0%,76%达到≥90%清除)和良好的总体安全性。
研究设计与样本
- 回顾性多中心研究,纳入200例于2024年10月至2026年1月期间在美国26家机构接受干预的患者。
- 纳入标准为年龄≥18岁、影像学确诊的急性(<14天)或亚急性(14-28天)静脉血栓栓塞症(VTE)成人患者。
主要发现
- 患者平均年龄64.5岁(范围25-90岁),女性占52%(n=104),男性占48%(n=96)。
- 平均每例治疗2.2个静脉节段(范围1-5),术前平均血栓负荷88.0%,术后降至10.5%,平均血栓清除率88.0%。
- 76.0%患者(n=152)达到≥90%血栓溶解;辅助旋转碎栓使用率30%,球囊静脉成形术38%,支架置入15%。
- 平均器械使用时间8.0分钟,平均每例2.4次器械通过,平均估计失血量320 mL(范围50-750 mL)。
- 总体并发症率2.4%(n=5),均为轻微入路部位血肿且非器械所致;200例队列中无器械相关严重不良事件。
关键数值与推荐
- 主要终点包括血栓清除有效性、静脉节段受累、估计失血量和术中不良事件发生率。
- 手术分类以外周静脉介入为主(70%),其余30%包括支架内再狭窄和经颈静脉肝内门体分流术修正等其他适应证。
临床怎么用
- 该真实世界数据支持CLEANER-Vac系统用于快速、单次session的VTE治疗,且出血风险和并发症相对可控。
- 与导管定向溶栓相比,该系统可能减少出血相关风险,但需前瞻性纵向研究评估长期结局和最佳患者分层。
局限性
- 本研究为回顾性设计,证据等级受限。
- 需前瞻性、纵向研究评估长期结局并明确最佳患者分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, represents a significant clinical entity associated with elevated morbidity and mortality rates. Conventional therapeutic approaches, such as systemic anticoagulation and thrombolytic agents, frequently yield suboptimal thrombus resolution. Mechanical thrombectomy has introduced a paradigm shift, enabling expeditious thrombus extraction while mitigating the chronic outcomes of suboptimally treated VTE and sequelae inherent to fibrinolytic therapies. The CLEANER Vac Thrombectomy System (Argon Medical Devices) is designed for controlled percutaneous venous thrombectomy. OBJECTIVE: To evaluate the real-world procedural efficacy, safety profile, and clinical utility of the CLEANER Vac system in a multicenter cohort comprising 200 patients presenting with symptomatic venous thrombus. METHODS: This retrospective, multicenter investigation included data from 200 patients who underwent intervention between October 2024 and January 2026 across 26 U.S. institutions. Eligible participants were adults aged ≥18 years with imaging-confirmed acute (<14 days) or subacute (14-28 days) VTE. Primary end points included thrombus clearance efficacy, segmented venous involvement, estimated blood loss, and intraprocedural adverse event incidence. RESULTS: The study cohort had a mean age of 64.5 (range, 25-90) years, with a gender distribution of 52% female (n = 104) and 48% male (n = 96). An average of 2.2 venous segments were treated per patient (range, 1-5). Mean preprocedure clot burden was 88.0%, which decreased to 10.5% postprocedure, culminating in a mean thrombus clearance of 88.0%. Overall, 76.0% of patients (n = 152) achieved ≥90% clot resolution. Adjunctive rotational maceration was used in 30% of cases, balloon venoplasty in 38%, and stent placement in 15%. Mean device utilization time was 8.0 minutes, with an average of 2.4 device passes per patient. Mean estimated blood loss was 320 (range, 50-750) mL. The overall complication rate was 2.4% (n = 5), consisting exclusively of minor access-site hematomas not attributed to the device. No serious adverse events were device-attributable within the 200-patient cohort. Procedures were predominantly classified as peripheral venous interventions (70%), with the remaining 30% encompassing alternative indications (eg, in-stent restenosis and transjugular intrahepatic portosystemic shunt revisions). CONCLUSIONS: In this cohort of 200 patients, the CLEANER Vac system demonstrated high procedural efficacy (88.0% mean clot clearance, 76% achieving ≥90% resolution) and a favorable overall safety profile. The findings support the potential role of this system in enabling rapid, single-session VTE treatment with constrained hemorrhagic liability and morbidity compared with catheter-directed thrombolysis. Prospective, longitudinal studies are warranted to evaluate long-term outcomes and delineate optimal patient stratification.
引用
- Sayfo S, Ishak CY, Rzadkowolsky-Raoli I, et al. Analysis of real-world multicenter experience with the large-bore CLEANER-Vac Thrombectomy System: An analysis of 200 patients. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42805291. doi:10.1016/j.jvsv.2026.102634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。